Rakuten Medical 首席执行官前田南美在八月于横滨的采访中表示，生物技术初创公司 Rakuten Medical 正在瞄准美国市场，推出其征服癌症的创新理念——光照疗法。
Rakuten Medical CEO Minami Maeda in an interview in Yokohama in August | Kazuaki Nagata By Kazuaki Nagata staff writer Oct 9, 2026 Biotech startup Rakuten Medical is eyeing the U.S. market for its novel idea to conquer cancer — light illumination therapy.
该治疗基于光免疫疗法——药物给药与红光照射相结合——长期作为其 Alluminox 平台的一部分进行研发。
The treatment, based on photoimmunotherapy — a combination of drug administration and illumination with red light — has long been in development as part of its Alluminox platform.
前田南美于七月成为 Rakuten Medical 的首席执行官，他在接受《日本时报》近期采访时表示：“我们相信这可能成为癌症治疗的新平台”。
“We believe this could become a new platform for cancer treatment,” Minami Maeda, who became CEO of Rakuten Medical in July, said in a recent interview with The Japan Times.